A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects wiht Residual or Recurrent Grade 2 Glioma wiht an IDH1 or IDH2 Mutation (INDIGO)

Clinical Trial Grant

Duke Scholars

Principal Investigator Katherine Barnett Peters Neurosurgery, Neuro-Oncology

Awarded By

Servier Pharmaceuticals

Start Date

March 30, 2020

End Date

January 31, 2026

Awarded By

Servier Pharmaceuticals

Start Date

March 30, 2020

End Date

January 31, 2026